Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 16/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26969706 | 0.91 | SIGMAR1 (0.47) | NPY5RSIGMAR1 | |
| SCHEMBL26969774 | 0.88 | CYP3A4 (0.48) | NPY5RHDAC1HDAC6ACLYHDAC8 | |
| SCHEMBL26969697 | 0.86 | SIGMAR1 (0.36) | NPY5RHDAC1HDAC6ACLYSIGMAR1 | |
| SCHEMBL26969759 | 0.85 | KDM4E (0.41) | NPY5RHDAC1HDAC6 | |
| SCHEMBL26969744 | 0.83 | HTR6 (0.40) | NPY5RACLYSIGMAR1 | |
| SCHEMBL30733398 | 0.81 | ACLY (0.43) | NPY5RHDAC1HDAC6ACLYHDAC8 | |
| SCHEMBL30733425 | 0.81 | CYP3A4 (0.43) | NPY5RACLY | |
| SCHEMBL25281945 | 0.80 | HTR6 (0.38) | NPY5RACLY | |
| SCHEMBL30733427 | 0.80 | ACLY (0.42) | NPY5RHDAC1HDAC6ACLYHDAC8 | |
| SCHEMBL25237936 | 0.79 | ACLY (0.41) | NPY5RACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | NPY5R 681/4885HDAC1 2067/4885HDAC6 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.